These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 26015868)

  • 21. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
    Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test.
    Cristescu R; Liu XQ; Arreaza G; Chen C; Albright A; Qiu P; Marton MJ
    BMC Cancer; 2022 Dec; 22(1):1310. PubMed ID: 36517748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic instability in non-breast/ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2.
    Elze L; van der Post RS; Vos JR; Mensenkamp AR; Pamidimarri Naga S; Hampstead JE; Vermeulen E; Oorsprong M; Hofste T; Simons M; Nagtegaal ID; Hoogerbrugge N; de Voer RM; Ligtenberg MJL
    J Natl Cancer Inst; 2024 Jul; ():. PubMed ID: 38960732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer.
    Jönsson JM; Bååth M; Björnheden I; Sahin ID; Måsbäck A; Hedenfalk I
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures.
    Diossy M; Sztupinszki Z; Borcsok J; Krzystanek M; Tisza V; Spisak S; Rusz O; Timar J; Csabai I; Fillinger J; Moldvay J; Pedersen AG; Szuts D; Szallasi Z
    NPJ Precis Oncol; 2021 Jun; 5(1):55. PubMed ID: 34145376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased Levels of Genomic Instability and Mutations in Homologous Recombination Genes in Locally Advanced Rectal Carcinomas.
    do Canto LM; Larsen SJ; Catin Kupper BE; Begnami MDFS; Scapulatempo-Neto C; Petersen AH; Aagaard MM; Baumbach J; Aguiar S; Rogatto SR
    Front Oncol; 2019; 9():395. PubMed ID: 31192117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
    Zhao EY; Shen Y; Pleasance E; Kasaian K; Leelakumari S; Jones M; Bose P; Ch'ng C; Reisle C; Eirew P; Corbett R; Mungall KL; Thiessen N; Ma Y; Schein JE; Mungall AJ; Zhao Y; Moore RA; Den Brok W; Wilson S; Villa D; Shenkier T; Lohrisch C; Chia S; Yip S; Gelmon K; Lim H; Renouf D; Sun S; Schrader KA; Young S; Bosdet I; Karsan A; Laskin J; Marra MA; Jones SJM
    Clin Cancer Res; 2017 Dec; 23(24):7521-7530. PubMed ID: 29246904
    [No Abstract]   [Full Text] [Related]  

  • 28. Expression of DNA Helicase Genes Was Correlated with Homologous Recombination Deficiency in Breast Cancer.
    Long M; Liu H; Wu J; Wang S; Liao X; Liu Y; Hu T
    Comput Math Methods Med; 2022; 2022():5508301. PubMed ID: 35855837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.
    von Wahlde MK; Timms KM; Chagpar A; Wali VB; Jiang T; Bossuyt V; Saglam O; Reid J; Gutin A; Neff C; Lanchbury JS; Hatzis C; Hofstatter E; Pusztai L
    Clin Cancer Res; 2017 Mar; 23(5):1193-1199. PubMed ID: 27601588
    [No Abstract]   [Full Text] [Related]  

  • 32. Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.
    Kraya AA; Maxwell KN; Wubbenhorst B; Wenz BM; Pluta J; Rech AJ; Dorfman LM; Lunceford N; Barrett A; Mitra N; Morrissette JJD; Feldman M; Nayak A; Domchek SM; Vonderheide RH; Nathanson KL
    Clin Cancer Res; 2019 Jul; 25(14):4363-4374. PubMed ID: 30914433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of PARP inhibitors in gynecological malignancies.
    Ang YLE; Tan DSP
    Curr Probl Cancer; 2017; 41(4):273-286. PubMed ID: 28583748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
    Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
    Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
    [No Abstract]   [Full Text] [Related]  

  • 35. Homologous recombination DNA repair defects in
    Li A; Geyer FC; Blecua P; Lee JY; Selenica P; Brown DN; Pareja F; Lee SSK; Kumar R; Rivera B; Bi R; Piscuoglio S; Wen HY; Lozada JR; Gularte-Mérida R; Cavallone L; ; Rezoug Z; Nguyen-Dumont T; Peterlongo P; Tondini C; Terkelsen T; Rønlund K; Boonen SE; Mannerma A; Winqvist R; Janatova M; Rajadurai P; Xia B; Norton L; Robson ME; Ng PS; Looi LM; Southey MC; Weigelt B; Soo-Hwang T; Tischkowitz M; Foulkes WD; Reis-Filho JS
    NPJ Breast Cancer; 2019; 5():23. PubMed ID: 31428676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial.
    Sipos O; Tovey H; Quist J; Haider S; Nowinski S; Gazinska P; Kernaghan S; Toms C; Maguire S; Orr N; Linn SC; Owen J; Gillett C; Pinder SE; Bliss JM; Tutt A; Cheang MCU; Grigoriadis A
    Ann Oncol; 2021 Jan; 32(1):58-65. PubMed ID: 33098992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    Cook SA; Tinker AV
    BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration.
    Tsang ES; Csizmok V; Williamson LM; Pleasance E; Topham JT; Karasinska JM; Titmuss E; Schrader I; Yip S; Tessier-Cloutier B; Mungall K; Ng T; Sun S; Lim HJ; Loree JM; Laskin J; Marra MA; Jones SJM; Schaeffer DF; Renouf DJ
    NPJ Precis Oncol; 2023 Mar; 7(1):31. PubMed ID: 36964191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.